John Kelly


John Kelly

CEO of Atomo Diagnostics

John has successfully worked in medical device product commercialisation for more than 15 years, focusing on the delivery of solutions that improve usability and reliability. He led the New Product Implementation Group at ResMed, where he managed the design and commercialisation of the Mirage Swift mask. John was Chief Operating Officer at ASX listed, now NASDAQ listed Unilife Corporation, where he led commercialisation of ‘Unifill’, the world’s first glass prefilled drug delivery device with integrated auto retract safety. This technology was licensed to Sanofi Aventis, securing US$47 million in licence and development fees.
John set up Atomo Diagnostics in 2010 to commercialise integrated diagnostics technology. AtomoRapid was a Gold Medal winner in the IVD Category and won 'Best in Show' at the 17th international Medical Design Exellence Awards (MDEA) event in New York which was the first diagnostics product to ever win best in show at MDEA. Most recently, Atomo Diagnostics was awarded a grant of A$1.8 million (US$1.3M) from the New South Wales Medical Device Fund 2015-2016 and US$6M from the Global Health Investment Fund to support the scale up of Atomo’s global health activities, focusing on continued rollout of its award winning AtomoRapid™ HIV test.
John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queens’s University Belfast, as well as an Executive MBA from the University of Sydney where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship.

Speaker’s event

Appearing Alongside

Related Speakers